<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01319929</url>
  </required_header>
  <id_info>
    <org_study_id>14165</org_study_id>
    <secondary_id>I4F-EW-CCAC</secondary_id>
    <nct_id>NCT01319929</nct_id>
  </id_info>
  <brief_title>A Study of LY2828360 in Patients With Osteoarthritic Knee Pain</brief_title>
  <official_title>A Proof of Concept Study of the Effects of LY2828360 in the Treatment of Patients With Osteoarthritic Knee Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety, efficacy and pharmacokinetics of single daily oral dose of
      LY2828360 in male and female subjects with osteoarthritic knee pain
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to 4 week endpoint in weekly mean of daily 24 hour Average Pain Scores (APS)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) of LY2828360, maximal concentration (Cmax)</measure>
    <time_frame>Pre-dose to 8 hours post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) of LY2828360, area under the concentration-time curve (AUC)</measure>
    <time_frame>Pre-dose to 8 hours post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 4 week endpoint in weekly mean of night pain and worst daily pain scores</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 4 week endpoint in Chronic Pain Sleep Inventory (CPSI)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 4 week endpoint in Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 4 week endpoint in Brief Pain Inventory (BPI) - Severity and Interference</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 4 week endpoint in Investigator Global Assessment of Changes (IGAC)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 4 week endpoint in Patient Global Assessment of Changes (PGAC)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 4 week endpoint in Western Ontario and MacMaster (WOMAC)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 4 week endpoint in Pain from 40 meter self-paced walk test</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 4 week endpoint in Time from the 11 step stair climb test</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 4 week endpoint in DoloTest sum score</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment emergent suicidal ideation and behaviors assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline up to 15 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>LY2828360 then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 milligrams (mg) of LY2828360 daily by mouth for 4 weeks: placebo daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then LY2828360</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo daily by mouth for 4 weeks: LY2828360 daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2828360</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2828360 then Placebo</arm_group_label>
    <arm_group_label>Placebo then LY2828360</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2828360 then Placebo</arm_group_label>
    <arm_group_label>Placebo then LY2828360</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are male or female patients with osteoarthritis (OA), as determined by medical history
             and physical examination. Males and females with stable medical problems that, in the
             investigator's opinion, will not significantly alter the disposition of the drug, will
             not place the patient at increased risk by participating in the study, and will not
             interfere with interpretation of the data.

               1. Male patients: agree to use a reliable method of birth control during the study
                  and for 3 months following the last dose of the investigational product

               2. Female patients: women not of child-bearing potential due to surgical
                  sterilization (at least 6 weeks post surgical bilateral oophorectomy with or
                  without hysterectomy or tubal ligation) confirmed by medical history, or
                  menopause

          -  Body weight greater than 40 kilograms (kg) and less than 120 kilograms (kg) with a
             body mass index (BMI) between 19-35 kilograms per square meter (kg/m^2) inclusive

          -  Patient with osteoarthritic knee based on disease diagnostic criteria as presented in
             the Inclusion Disease Criteria, below

          -  Blood pressure and pulse rate in supine and standing positions, within normal
             reference ranges for the population and investigator clinical research unit (CRU), or
             results with acceptable deviations that are judged to be not clinically significant by
             the investigator

          -  Have clinical laboratory test results within normal reference range for the population
             or investigator clinical research unit (CRU), or results with acceptable deviations
             that are judged to be not clinically significant by the investigator

          -  Have venous access sufficient to allow for blood sampling

          -  Have agreed to maintain the same activity level throughout the course of the study

        Inclusion Disease Criteria:

          -  Have a unilateral or bilateral osteoarthritis (OA) of the knee diagnosed according to
             the American College of Rheumatology (ACR) criteria. The clinical diagnosis of
             osteoarthritis (OA) will be confirmed by the American College of Rheumatology (ACR)
             clinical and radiographic criteria for classification of idiopathic osteoarthritis
             (OA) of the knee based upon the following criteria:

               1. Knee pain for at least 14 days per month for the 3 months before screening

               2. Osteophytes (with radiographic evidence)

               3. At least 1 of the following 3 conditions: Age greater than 50, or Morning
                  stiffness less than 30 minutes, or Crepitus

          -  Have a Kellgren and Lawrence grade of I, II, III or IV

          -  Have a mean score of at least 4 (moderate) and less than or equal to 8
             (moderate-severe) on the 24-hour average pain score (0-10) (question 1) in the patient
             e-diary from screening to randomization for the knee joint during walking

          -  Discontinued use of all analgesic medications (including over-the-counter [OTC]
             analgesics/Non-Steroidal Anti-Inflammatory Drug [NSAID]) at least 2 weeks prior to
             randomization (patients are allowed limited use of analgesic medications)

        Exclusion Criteria:

          -  Are currently enrolled in, have completed or discontinued within the last 3 months
             from, a clinical trial involving an off-label investigational drug or device or are
             concurrently enrolled in any other type of medical research judged not to be
             scientifically or medically compatible with this study

          -  Have known allergies to LY2828360, related compounds or any components of the
             formulation

          -  Have an abnormality in the 12-lead electrocardiogram (ECG) at screening that, in the
             opinion of the investigator, increases the risks associated with participation in the
             study

          -  Have a recent or current history of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data

          -  Have current or previous (within the past year) Axis 1 diagnosis of major depressive
             disorder, mania, bipolar disorder, psychosis, dysthymia, generalized anxiety disorder,
             alcohol or eating disorders according to the Diagnostic and Statistical Manual of
             Mental Disorders, Fourth Edition Text Revision, criteria, as determined by the
             investigator and confirmed by the Mini-International Neuropsychiatric Interview

          -  Are judged by the Principal Investigator to be clinically at suicidal risk based upon
             clinical interview

          -  Have intercurrent illness or clinically significant adverse events

          -  Have increased risk of seizures as evidenced by a history of seizures, stroke, surgery
             to the cerebral cortex, or head trauma with loss of consciousness

          -  Have an alanine aminotransaminase (ALT) greater than 2.5 times Upper Limit of Normal
             (ULN) at Screening, based on reference ranges of the local laboratory. Moderate or
             greater hepatic impairment

          -  Have prior renal transplant, current renal dialysis or severe renal insufficiency, or
             serum creatinine laboratory value greater than 1.5 times Upper Limit of Normal, based
             on the reference ranges of the local laboratory

          -  Have clinically significant abnormal neurological examination, especially any evidence
             of tremor or nystagmus

          -  Have a history of or symptoms suggestive of sleep apnoea

          -  Use of any known strong inducers or inhibitors of Cytochrome P450 within 30 days prior
             to enrolment.

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening

          -  Have a positive alcohol breath test at Screening

          -  Show evidence of human immunodeficiency virus infection and/or positive human HIV
             antibodies

          -  Have an active malignancy of any type or a history of malignancy (except basal cell
             carcinoma of the skin that has been excised prior to study start)

          -  Are at a high risk of infection

          -  Have an autoimmune disorder

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody

          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen

          -  Are women with a positive pregnancy test or women who are lactating or child bearing

          -  Use prescription and herbal medications that cannot safely be discontinued by end of
             screening

          -  Have donated blood of more than 500 milliliters (mL) within the last 3 months

          -  Have an average weekly alcohol intake that exceeds 21 units per week (males up to age
             65) and 14 units per week (males over 65 and females), or are unwilling to refrain
             alcohol consumption for the duration of the study

          -  Are persons who have previously received the investigational product in study, have
             completed or withdrawn from this study or any other study investigation LY2828360

          -  Are taking any excluded medications (analgesic medications) and over-the- counter
             medications that cannot be discontinued at screening

          -  Show evidence or have any prior history of significant active neurological or
             psychiatric disease including depression

        Exclusion Disease Criteria:

          -  Have secondary causes of arthritis of the knee including septic arthritis,
             inflammatory joint disease, articular fracture, major dysplasias or congenital
             abnormality, ochronosis, acromegaly, hemochromatosis, Wilson's disease, and primary
             osteochondromatosis

          -  Have had lower extremity surgery (including arthroscopy of the index knee) within 6
             months prior to Screening or have surgery planned of the index knee at anytime

          -  Have had significant prior injury to the index knee within 12 months prior to
             Screening

          -  Use of lower extremity assistive devices other than a cane or knee brace (use of a
             'shoe lift' is permitted). Are non-ambulatory or require the use of crutches or a
             walker. Use of a cane in the hand opposite the index knee is acceptable

          -  Have a confounding painful condition that may interfere with assessment of the index
             joint, i.e., knee

          -  Have any other musculoskeletal or arthritic condition that may affect the
             interpretation of clinical efficacy and/or safety data or otherwise contraindicates
             participation in this clinical study

          -  Have used corticosteroid prior to baseline

          -  Have received hyaluronan injections into index knee within the previous 6 months prior
             to Treatment Phase day 3

          -  Have initiated or have changed to an established physiotherapy program within 2 weeks
             prior to Treatment Phase day 3 or during the study period An established physiotherapy
             program may be continued throughout the study period if unchanged in frequency and
             intensity

          -  Has had a prior synovial fluid analysis showing a White Blood Cell (WBC) greater than
             or equal to 2000 cubic millimeters (mm^3) that is indicative of a diagnosis other than
             OA

          -  Have started recently or changed dose regimen of any OA specific therapies (i.e.,
             nutraceutical products)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <disposition_first_submitted>May 23, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 23, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 31, 2012</disposition_first_posted>
  <last_update_submitted>May 23, 2012</last_update_submitted>
  <last_update_submitted_qc>May 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis, knee pain, osteoarthritic knee pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

